Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 9/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MARS1 | P56192 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3846339 | 0.80 | ALPL (0.49) | MAPTALPLIDO1MAPK1KMT2A | |
| SCHEMBL18952795 | 0.77 | CNR1 (0.41) | DPP4 | |
| SCHEMBL4972450 | 0.77 | GSK3B (0.44) | MAPTHPGDKMT2AHSP90AB1CRHR1 | |
| SCHEMBL4969790 | 0.76 | CRHR1 (0.39) | MAPTHPGDHSP90AA1HSP90AB1CRHR1 | |
| SCHEMBL4972454 | 0.74 | IDO1 (0.50) | MAPTHPGDIDO1 | |
| SCHEMBL4971006 | 0.74 | PIM1 (0.48) | MAPTHPGDALPLIDO1MAPK1 | |
| SCHEMBL6639801 | 0.73 | CYP3A4 (0.41) | MAPTHPGDHSP90AA1HSP90AB1CYP3A4 | |
| SCHEMBL6544085 | 0.71 | — | — | |
| SCHEMBL4973922 | 0.71 | CRHR1 (0.37) | HSP90AA1HSP90AB1CRHR1DPP4 | |
| SCHEMBL4975912 | 0.71 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653970-A4 | GSK-3 INHIBITORS AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1653970-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| WO-2005039485-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | MAPT 146/4885HPGD 1602/4885ALPL 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.